BPG is committed to discovery and dissemination of knowledge
Retrospective Study Open Access
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123688
Published online Nov 15, 2026. doi: 10.4251/wjgo.123688
Occult pancreatic ductal adenocarcinoma in patients undergoing invasive evaluation for chronic pancreatitis: A retrospective study
Wan-Zhen Wei, Kong-Yuan Wei, Xue Yang, Liang Han, Zheng Wang, Wan-Xing Duan, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an 710061, Shaanxi Province, China
Wan-Zhen Wei, Kong-Yuan Wei, Xue Yang, Liang Han, Zheng Wang, Wan-Xing Duan, Pancreatic Disease Center, Xi'an Jiaotong University, Xi’an 710061, Shaanxi Province, China
Hai-Rong He, Clinical Research Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an 710061, Shaanxi Province, China
Hao-Ze Leng, Health Science Center, Xi’an Jiaotong University, Xi’an 710061, Shaanxi Province, China
Yi-Na Jiang, Department of Pathology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an 710061, Shaanxi Province, China
Jing Xue, Shanghai Cancer Institute, Renji Hospital, Shanghai 200127, Shanghai, China
ORCID number: Hai-Rong He (0000-0002-6988-6423); Xue Yang (0000-0002-7906-2612); Zheng Wang (0000-0002-0490-466X); Wan-Xing Duan (0000-0002-1839-8016).
Co-corresponding authors: Zheng Wang and Wan-Xing Duan.
Author contributions: Wei WZ analyzed the data and drafted the original manuscript; Leng HZ collected the clinical data of the patients; He HR conducted the statistical analysis and interpreted the data; Jiang YN performed the pathological review; Wei KY, Yang X, Han L, and Xue J critically revised the manuscript for important intellectual content; all authors critically reviewed the manuscript, approved the final version for publication, and were responsible for the decision to submit the manuscript for publication; and Wang Z and Duan WX contributed equally to this work as co-corresponding authors, with equal responsibilities in obtainment of funding and contributions to the study conception and design, data analysis and interpretation, manuscript revision, and final approval of the version to be published.
AI contribution statement: AI tools were not used to generate original scientific data, perform independent scientific analyses, or draw scientific conclusions.
Supported by National Natural Science Foundation of China, No. 82372895 and No. 82172853; the Key Research and Development Program of Shaanxi, No. 2024SF2-GJHX-03; the Natural Science Foundation of Shaanxi Province, No. 2023-JC-ZD-54; and the Innovative Team Foundation of Shaanxi Health Commission, No. 2024TD-16.
Institutional review board statement: This study was approved by the Medical Ethics Committee of the First Affiliated Hospital of Xi'an Jiaotong University (No. XJTU1AF2024LSYY-446).
Informed consent statement: The need for patient consent was waived owing to the retrospective nature of the study.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Data sharing statement: No additional data are available.
Corresponding author: Wan-Xing Duan, MD, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, No. 277 West Yanta Road, Xi’an 710061, Shaanxi Province, China. 15339184808@163.com
Received: May 27, 2026
Revised: July 17, 2026
Accepted: August 28, 2026
Published online: November 15, 2026
Processing time: 163 Days and 2.4 Hours

Abstract
BACKGROUND

Chronic pancreatitis (CP) is a well-established risk factor for pancreatic ductal adenocarcinoma (PDAC); however, the overlapping clinical and imaging features of the two conditions make early differentiation particularly challenging.

AIM

To identify independent risk factors for occult PDAC in patients with CP undergoing invasive diagnostic or surgical procedures.

METHODS

We conducted a retrospective cohort study of 359 patients with CP who underwent invasive diagnostic or surgical procedures between 2013 and 2023. Patients were classified according to histopathological findings obtained from surgical specimens or fine-needle biopsy. Clinical characteristics, radiological findings, and laboratory parameters were analyzed. Least absolute shrinkage and selection operator (LASSO) regression was applied for variable selection, followed by multivariable logistic regression to identify independent risk factors associated with PDAC.

RESULTS

Among the 359 patients with CP, 33 (9.20%) were histopathologically diagnosed with PDAC. LASSO regression identified pancreatic mass, main pancreatic duct stones, blood urea nitrogen, serum ionized calcium, carbohydrate antigen 19-9 (CA19-9), and carcinoembryonic antigen (CEA) as candidate factors. Multivariable logistic analysis demonstrated that elevated serum ionized calcium [odds ratio (OR) = 2.67, 95% confidence interval (95%CI): 1.23-6.88, P = 0.015], CA19-9 (OR = 2.83, 95%CI: 1.79-5.26, P < 0.001), and CEA (OR = 1.52, 95%CI: 1.05-2.17, P = 0.026) were independently associated with the presence of PDAC.

CONCLUSION

Among patients with CP requiring invasive procedures, 9.20% were histopathologically diagnosed with PDAC. Elevated serum ionized calcium, CA19-9, and CEA levels were identified as independent risk factors.

Key Words: Pancreatic ductal adenocarcinoma; Chronic pancreatitis; Carbohydrate antigen 19-9; Carcinoembryonic antigen; Serum ionized calcium

Core Tip: Chronic pancreatitis (CP) is a well-established risk factor for pancreatic ductal adenocarcinoma (PDAC), yet distinguishing between the two conditions remains clinically challenging. In this study, 9.2% of 359 patients with CP who underwent invasive procedures were histopathologically diagnosed with occult PDAC. Elevated serum ionized calcium, carbohydrate antigen 19-9 (CA19-9), and carcinoembryonic antigen (CEA) levels were identified as independent predictors of occult malignancy, with dual markers of CA19-9 and CEA showing particular diagnostic value. Patients with CP are at risk of missed PDAC diagnosis. Our study identified readily available biomarkers to guide the detection of PDAC in this high-risk population.



INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies worldwide, with a 5-year relative survival rate of only 13%[1]. Despite advances in oncologic therapy, its incidence continues to rise by approximately 1% annually, and it is projected to become the second leading cause of cancer-related death by 2030[2]. The poor prognosis of PDAC is largely attributable to delayed diagnosis, as early-stage disease is typically asymptomatic or presents with nonspecific manifestations. Consequently, fewer than 20% of patients are eligible for potentially curative surgical resection at the time of diagnosis[3]. Given the aggressive nature of PDAC and its propensity for early metastatic spread, timely detection is critical for improving clinical outcomes. In this context, chronic pancreatitis (CP) has been identified as a well-established risk factor and precursor condition for PDAC, providing a potential window for early detection and intervention.

CP is a progressive fibroinflammatory disorder characterized by irreversible pancreatic injury[4] and is a well-established risk factor for PDAC. Epidemiological studies have determined that patients with CP carry at least a 13-fold increased risk of developing pancreatic cancer compared with the general population[5,6]. However, distinguishing PDAC from CP in clinical practice remains particularly challenging. Both conditions may present with overlapping symptoms, including abdominal pain, pancreatic ductal obstruction, and mass-forming lesions. In addition, the chronic inflammatory and fibrotic changes associated with CP can obscure or mimic underlying malignancy on imaging[7,8]. The diagnostic ambiguity is further compounded by the temporal relationship between CP and PDAC. Previous studies have demonstrated that the risk of PDAC is highest shortly after the diagnosis of CP and gradually declines with longer follow-up[9]. Pooled estimates indicate a 16.16-fold increased risk within the first 2 years after CP diagnosis, decreasing to 7.90-fold at 5 years and to 3.53-fold after 9 or more years[10]. These findings raise the possibility that some PDAC cases may have been initially misclassified as CP. Indeed, a large cohort study involving 471992 veterans found that approximately 5% of patients ultimately diagnosed with PDAC were initially misdiagnosed with CP, with nearly two-thirds experiencing diagnostic delays exceeding 2 months[11]. These observations underscore the clinical importance of identifying PDAC in patients presenting with CP, particularly when invasive diagnostic or therapeutic procedures are considered.

In clinical practice, patients with CP frequently undergo invasive treatments, including endoscopic and surgical procedures, for the management of complications or when malignancy cannot be definitively excluded based on imaging findings alone. These interventions often provide an opportunity for histopathological evaluation and may reveal previously unrecognized malignancy. However, the prevalence of underlying PDAC among patients undergoing invasive treatment for CP remains insufficiently defined, and the clinical characteristics that may indicate an increased risk of undiagnosed malignancy in this population have not been well established. Therefore, the present study aimed to determine the prevalence of histopathologically confirmed PDAC in patients undergoing invasive treatment for CP and to identify potential clinical, radiological, and laboratory predictors that may facilitate earlier detection of pancreatic cancer in this high-risk population.

MATERIALS AND METHODS
Study design and participants

This retrospective cohort study included patients diagnosed with CP who were admitted to the First Affiliated Hospital of Xi’an Jiaotong University between January 2013 and December 2023. Patients were screened according to established diagnostic criteria for CP[12]. Invasive procedures were performed either to exclude malignancy or to manage CP-related complications, including main pancreatic duct obstruction, pancreatic duct stones, or symptoms refractory to pharmacological treatment[13,14]. Procedural records were retrospectively reviewed, and histopathological findings from surgical specimens or biopsy samples were examined.

Inclusion criteria: (1) A clinical diagnosis of CP established according to accepted diagnostic criteria before invasive intervention; and (2) Availability of pathological confirmation obtained during the procedure.

Exclusion criteria: (1) Age younger than 18 years; (2) Inconclusive pathological findings, including cases with only cytological results or nonspecific pancreatic tissue without a definitive diagnosis; (3) A pre-existing diagnosis of PDAC or other pancreatic neoplasms (e.g., pancreatic neuroendocrine tumors or solid pseudopapillary neoplasms) established before the invasive procedure based on medical history, laboratory tests, or imaging findings; (4) Presence of malignancies in other organs; or (5) Missing data exceeding 15% of the total dataset.

Patients were categorized into two groups based on pathological findings: CP with PDAC and CP without PDAC. All pathological diagnoses were independently reviewed and reconfirmed by experienced pathologists.

Data collection and variables

Demographic and clinical information was retrieved from the hospital medical records system, including age, sex, body mass index, symptom duration as documented in the medical history (hereafter referred to as “duration”), clinical symptoms (jaundice, abdominal pain, and weight loss), and medical history (acute pancreatitis, diabetes mellitus, hypertension, smoking status, and alcohol consumption). Weight loss was defined as an unintentional reduction of more than 5% of baseline body weight within 6 months. Heavy alcohol consumption was defined as alcohol intake exceeding 60 mL per day.

Radiological features were obtained from contrast-enhanced computed tomography (CT) imaging reports and evaluated by 2 experienced abdominal radiologists for pancreatic atrophy, parenchymal calcification, main pancreatic duct stones, space-occupying lesions (pancreatic masses), and cystic lesions. In cases of discrepancy between the reports and the radiologists' re-interpretation, the ground truth was determined by the senior radiologist. A pancreatic mass was defined as a hypoattenuating and hypoenhancing lesion on multidetector CT[8]. Pancreatic atrophy was defined as diffuse parenchymal thinning (mean thickness less than 20 mm) or partial parenchymal invagination (width from the main pancreatic duct wall of no more than 4 mm)[15].

Laboratory test results were obtained at hospital admission. These anonymized clinical data were collected from the Biobank and Network and Information Center of the First Affiliated Hospital of Xi’an Jiaotong University. Detailed laboratory variables included in the analysis are presented in the “Results” section.

Statistical analysis

Baseline characteristics were compared between groups using appropriate statistical methods. The normality of continuous variables was assessed using the Shapiro-Wilk test. Normally distributed variables were expressed as mean ± SD and compared using the independent-samples t-test. Non-normally distributed variables were presented as median [interquartile range (IQR)] and compared using the Mann-Whitney U test. Categorical variables were summarized as n (%) and compared using the χ2 test or Fisher’s exact test, as appropriate. A two-sided P value < 0.05 was considered statistically significant. Multicollinearity among candidate variables was assessed using the variance inflation factor (VIF), with VIF values > 10 indicating significant multicollinearity. Variables with missing values exceeding 15% of the total study population were excluded from further analysis. For the remaining variables, missing data were imputed using the random forest algorithm implemented in the missForest R package with 1000 trees and a node size of 5.

Given the relatively large number of candidate variables and the limited number of outcome events, variable selection was performed before multivariable regression analysis to reduce the risk of model overfitting. The least absolute shrinkage and selection operator (LASSO) regression was applied for feature selection, with the optimal regularization parameter (λ) determined by 10-fold cross-validation. The final LASSO model was selected based on the λ value between the minimum cross-validation error (λ_min) and the value within one standard error of the minimum (λ_1se). Variables retained in the LASSO model were subsequently entered into a multivariable logistic regression model to identify independent predictors of PDAC. Continuous variables were standardized before inclusion in the regression analysis.

All statistical analyses were performed using R software version 4.4.2 (R Foundation for Statistical Computing, Vienna, Austria; https://www.R-project.org/). This study was conducted in accordance with the STROBE reporting guideline for observational studies.

Ethical approval

All participant data were anonymized to ensure confidentiality. This study adhered to the principles of the Declaration of Helsinki. The study protocol was approved by the Medical Ethics Committee of the First Affiliated Hospital of Xi'an Jiaotong University (No. XJTU1AF2024LSYY-446), which waived the requirement for obtaining informed consent owing to the retrospective nature of the study.

RESULTS
Patient selection and cohort characteristics

A total of 391 patients admitted with a diagnosis of CP who underwent histopathological evaluation were initially screened. Among them, 32 patients were excluded according to the predefined criteria: Eight patients aged < 18 years, seven with inconclusive pathology (cytology only or nonspecific pancreatic tissue), nine with preoperatively diagnosed pancreatic neoplasms (including PDAC, pancreatic mucinous tumors, pancreatic neuroendocrine tumors, and intraductal papillary mucinous neoplasms), four with malignant tumors in other organs, and four with missing data. Ultimately, 359 patients were included in the final analysis (Figure 1).

Figure 1
Figure 1 Flow diagram of patient selection and study cohort classification. CP: Chronic pancreatitis; PDAC: Pancreatic ductal adenocarcinoma.

Among these patients, 33 (9.20%) were diagnosed with PDAC based on final histopathological examination and were classified as the CP-PDAC group (tumor-stage stratification data are listed in Supplementary Table 1). The remaining patients were categorized as the non-PDAC group, which included 319 cases with confirmed CP and 7 cases with other pancreatic diseases. These 7 cases consisted of 2 mucinous cystadenomas, 2 intraductal papillary mucinous neoplasms, 1 serous cystadenoma, 1 solid pseudopapillary tumor, and 1 neuroendocrine tumor.

The cohort included 285 male patients (79.39%). The median age of the entire cohort was 52 (IQR: 42-61) years. Autoimmune pancreatitis was diagnosed in 67 patients (19.10%). Surgical pathology specimens were available for 295 patients (82.17%), whereas the remaining patients underwent histopathological evaluation through endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA). Among the PDAC cases, 29 were diagnosed by surgical pathology and 4 by EUS-FNA. Variables excluded because of excessive missing data are listed in Supplementary Table 2. No significant multicollinearity was detected among candidate variables (Supplementary Table 3).

Additionally, enrolled patients were admitted to the Departments of Hepatobiliary Surgery (310 cases, 86.35%), Departments of Gastroenterology (13 cases, 3.62%), or Departments of Geriatric Surgery (36 cases, 10.03%). The radiologists’ interpretations were in agreement with the original reports. All 74 cyst cases were unilocular thin-wall (< 2 mm) pseudocysts without enhancing solid components or septations. A total of 45 patients presented with painless jaundice, among whom 5 (11.11%) were diagnosed with PDAC. Abdominal pain severity was quantified using the preoperative Numeric Rating Scale; for patients with abdominal pain, the median score was 2 (IQR: 1-3.25; range: 1-5).

Baseline characteristics

Baseline characteristics of the CP-PDAC and non-PDAC groups are summarized in Table 1. Missing data were imputed using the random forest method, and the imputed dataset showed balanced variable distributions (Supplementary Table 4).

Table 1 Baseline characteristics and variables of patients with chronic pancreatitis with and without pancreatic ductal adenocarcinoma.
Characteristics
Overall, n = 359
Non-PDAC, n = 326
CP-PDAC, n = 33
P value
Age (years)52 (42, 61)52 (41, 60)54 (48, 62)0.256
BMI (kg/m2)21.07 (19.13, 22.76)21.09 (19.14, 22.80)20.78 (19.12, 22.42)0.658
Sex1.000
    Female74 (20.61)67 (20.55)7 (21.21)
    Male285 (79.39)259 (79.45)26 (78.79)
Imaging features
    Atrophy0.464
        No304 (84.68)278 (85.28)26 (78.79)
        Yes55 (15.32)48 (14.72)7 (21.21)
    Mass0.022
        No224 (62.40)210 (64.42)14 (42.42)
        Yes135 (37.60)116 (35.58)19 (57.58)
    Calcification0.73
        No235 (65.46)212 (65.03)23 (69.70)
        Yes124 (34.54)114 (34.97)10 (30.30)
    Stone0.021
        No198 (55.15)173 (53.07)25 (75.76)
        Yes161 (44.85)153 (46.93)8 (24.24)
    Cyst0.753
        No285 (79.39)260 (79.75)25 (75.76)
        Yes74 (20.61)66 (20.25)8 (24.24)
Clinical features
    Duration (days)31 (13, 153)31 (13, 169)28 (10, 91)0.115
    Jaundice0.147
        No271 (75.49)250 (76.69)21 (63.64)
        Yes88 (24.51)76 (23.31)12 (36.36)
    Abdominal pain0.301
        No110 (30.64)103 (31.60)7 (21.21)
        Yes249 (69.36)223 (68.40)26 (78.79)
    Weight loss0.567
        No202 (57.71)185 (58.36)17 (51.52)
        Yes148 (42.29)132 (41.64)16 (48.48)
    Acute pancreatitis0.873
        No292 (81.34)266 (81.60)26 (78.79)
        Yes67 (18.66)60 (18.40)7 (21.21)
    Diabetes mellitus0.529
        No292 (81.34)267 (81.90)25 (75.76)
        Yes67 (18.66)59 (18.10)8 (24.24)
    Hypertension0.896
        No302 (84.12)275 (84.36)27 (81.82)
        Yes57 (15.88)51 (15.64)6 (18.18)
    Smoking index0.696
        0193 (53.76)175 (53.68)18 (54.55)
        < 40063 (17.55)59 (18.10)4 (12.12)
        400-79966 (18.38)60 (18.40)6 (18.18)
        ≥ 80037 (10.31)32 (9.82)5 (15.15)
    Drinking0.668
        None259 (72.14)233 (71.47)26 (78.79)
        Moderate41 (11.42)38 (11.66)3 (9.09)
        Heavy59 (16.43)55 (16.87)4 (12.12)
Laboratory test
    MPV (fL)11.1 (10.1, 12.2)11.1 (10.1, 12.2)11.1 (10.0, 12.5)0.488
    PLT (× 109/L)197 (156, 251)198 (156, 251)193 (146, 251)0.731
    LYM (× 109/L)1.42 (1.07, 1.85)1.42 (1.09, 1.87)1.20 (1.04, 1.58)0.176
    WBC (× 109/L)5.66 (4.61, 7.23)5.69 (4.60, 7.23)5.58 (4.99, 7.61)0.563
    HGB (g/L)132 (119, 142)132 (120, 142)126 (111, 139)0.156
    HCT (%), mean ± SD39.8 (5.45)40.0 (5.38)38.0 (5.94)0.047
    RBC (× 109/L), mean ± SD4.26 (0.59)4.28 (0.58)4.07 (0.62)0.051
    GLU (mmol/L)5.56 (4.88, 6.66)5.56 (4.89, 6.56)5.64 (4.76, 7.22)0.746
    CRE (μmol/L)53.0 (45.0, 62.0)53.0 (44.5, 62.0)53.0 (48.0, 64.0)0.659
    BUN (mmol/L)4.70 (3.79, 5.98)4.69 (3.78, 5.93)5.49 (4.16, 7.09)0.051
    ALB (g/L), mean ± SD39.04 (5.82)39.06 (5.81)38.93 (5.93)0.904
    TP (g/L), mean ± SD66.88 (8.51)66.98 (8.55)65.97 (8.20)0.517
    DBIL (µmol/L)5.30 (3.40, 16.10)5.30 (3.40, 12.80)7.60 (4.00, 111.40)0.062
    ALT (U/L)34.00 (20.00, 86.00)32.50 (19.00, 83.75)56.00 (27.00, 98.00)0.019
    AST (U/L)27.00 (19.00, 59.00)26.00 (19.00, 57.00)30.00 (22.00, 66.00)0.166
    Calcium (mmol/L)2.20 (2.11, 2.32)2.19 (2.10, 2.32)2.27 (2.19, 2.31)0.077
    DD (mg/L)0.64 (0.43, 1.02)0.64 (0.44, 1.04)0.50 (0.42, 1.00)0.747
    FIB (g/L)3.48 (2.79, 4.24)3.45 (2.79, 4.23)3.73 (2.82, 4.26)0.394
    INR1.03 (0.97, 1.09)1.03 (0.97, 1.09)1.03 (0.98, 1.08)0.961
    PT (seconds)12.9 (11.9, 13.8)12.9 (11.9, 13.8)12.9 (12.0, 14.0)0.489
    CA19-9 (U/mL)21.18 (9.29, 64.63)18.09 (8.72, 49.42)186.20 (39.27, 789.40)< 0.001
    CA125 (U/mL)13.60 (9.50, 23.50)13.20 (9.24, 22.75)20.75 (11.65, 34.06)0.021
    CEA (ng/mL)2.47 (1.59, 3.50)2.38 (1.52, 3.24)3.55 (2.50, 6.78)< 0.001

There was no significant difference in sex distribution between the two groups. Regarding imaging findings, pancreatic masses were more frequently observed in the CP-PDAC group (P = 0.022), whereas main pancreatic duct stones were less common (P = 0.021). No significant differences were identified in chief complaints, clinical symptoms, or lifestyle factors, including weight loss, smoking, and alcohol consumption. Laboratory comparisons revealed significant differences in hematocrit (P < 0.05), alanine aminotransferase (P < 0.05), carbohydrate antigen 19-9 (CA19-9) (P < 0.001), cancer antigen 125 (P < 0.05), and carcinoembryonic antigen (CEA) levels (P < 0.001) between the two groups.

Variable selection and logistic regression analysis

Variable selection was performed using LASSO regression (Figure 2A). Depending on the regularization parameter (λ), the number of selected variables ranged from 1 to 10. A sequence of λ values between λ_min and λ_1se was evaluated (Figure 2B).

Figure 2
Figure 2 Least absolute shrinkage and selection operator regression analysis for variable selection. A: Least absolute shrinkage and selection operator coefficient profiles of candidate variables plotted against log(λ); B: Ten-fold cross-validation plot for selection of the optimal regularization parameter (λ). The vertical dashed lines indicate λ_min and λ_1se, corresponding to the minimum cross-validation error and the value within one standard error of the minimum, respectively. LASSO: Least absolute shrinkage and selection operator.

Based on this approach, six variables were retained for subsequent analysis: Pancreatic mass, main pancreatic duct stones, blood urea nitrogen, serum ionized calcium, CA19-9, and CEA. The LASSO regression coefficients for variable selection are presented in Supplementary Table 5.

These six variables were included in a multivariable logistic regression model. The analysis demonstrated that elevated preoperative serum ionized calcium (OR = 2.67, 95%CI: 1.23-6.88, P = 0.015), CA19-9 (OR = 2.83, 95%CI: 1.79-5.26, P < 0.001), and CEA (OR = 1.52, 95%CI: 1.05-2.17, P = 0.026) were independently associated with the presence of PDAC (Figure 3).

Figure 3
Figure 3 Forest plot of multivariate logistic regression analysis for early detection of pancreatic cancer ductal adenocarcinoma in patients with chronic pancreatitis. BUN: Blood urea nitrogen; CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; 95%CI: 95% confidence interval; OR: Odds ratio.
Subgroup analysis of patients with elevated CA19-9

Given that CA19-9 is a widely used biomarker for PDAC, a subgroup analysis was conducted among patients with elevated CA19-9 levels (> 37 U/mL). In the original dataset, 113 patients had elevated CA19-9 levels, among whom 25 (22.12%) were diagnosed with PDAC. After imputation, 134 patients were classified as having elevated CA19-9 levels, including the same 25 PDAC cases (18.66%; Supplementary Table 6). For consistency, the imputed dataset was used in subsequent analyses.

Owing to the limited sample size within this subgroup, the variables previously selected by LASSO regression were retained. Among these variables, only CEA remained significantly associated with PDAC (OR = 1.86, 95%CI: 1.24-2.84, P = 0.003; Supplementary Figure 1).

Sensitivity analysis for bilirubin

As bilirubin levels may influence CA19-9 concentrations, a sensitivity analysis was performed to evaluate this potential confounding effect. In the original dataset, elevated bilirubin levels (direct bilirubin > 5.1 μmol/L) were observed in 190 patients. The median CA19-9 level was significantly higher in patients with elevated bilirubin levels (36.02 U/mL, 11.65-113.35 U/mL) than in those without bilirubin elevation (12.61 U/mL, 7.1-27.6 U/mL; P < 0.001).

When bilirubin was included in the multivariable model for the entire cohort, it did not significantly affect the association between CA19-9 and PDAC (OR = 0.83, 95%CI: 0.49-1.30, P = 0.455), indicating that the main findings remained robust (Supplementary Figure 2). Furthermore, no significant difference in bilirubin distribution was observed within the subgroup of patients with elevated CA19-9 levels (Supplementary Table 6).

DISCUSSION

In this cohort of patients with CP undergoing invasive diagnostic or therapeutic procedures, the prevalence of histopathologically confirmed PDAC was 9.2%. Elevated serum ionized calcium, CA19-9, and CEA levels were independently associated with the presence of occult malignancy. Notably, among individuals with elevated CA19-9, CEA remained a statistically significant independent risk factor. Thus, our findings support the use of CA19-9 and CEA as dual biomarkers for assessing the risk of undiagnosed pancreatic cancer in patients with CP. These findings highlight the substantial burden of occult PDAC among high-risk patients with an established CP diagnosis, especially those requiring surgical intervention or presenting with suspected malignancy. Although novel techniques and artificial intelligence-assisted diagnostics are emerging, our study employs the most accessible clinical indicators[16-18], providing a practical strategy for detecting underlying pancreatic cancer in patients with CP. In particular, the combined assessment of CA19-9 and CEA, along with elevated serum ionized calcium levels, may facilitate risk stratification and improve the detection of occult PDAC in this high-risk population.

In our study, we selected patients with CP who underwent invasive diagnostic or therapeutic procedures to provide a histopathologically confirmed diagnostic gold standard. At the same time, this design restricted the population to a well-defined clinical subgroup, namely patients with refractory symptoms, diagnostic uncertainty, or structural complications necessitating invasive evaluation. The observed prevalence of PDAC (9.2%) substantially exceeded the cumulative incidence rates reported in longitudinal cohort studies of unselected patients with CP, which range from 1.8% at 10 years to 4% at 20 years of follow-up[19]. This discrepancy was expected, as our cohort captured a higher-risk subgroup.

Epidemiological data indicate that the relative risk of PDAC is highest within the first 2 years of CP diagnosis (approximately 16-fold) and gradually declines thereafter[9,10]. These temporal dynamics raise the possibility that some cases of PDAC may be initially misclassified as CP. Indeed, previous studies have demonstrated that approximately 5% of patients ultimately diagnosed with PDAC were initially misdiagnosed as having CP, often delaying cancer diagnosis by more than 2 months[11]. Our findings extend these observations by quantifying the diagnostic yield of histopathological examination during invasive procedures, underscoring the diagnostic opportunity provided by such interventions.

Serum ionized calcium emerged as an independent factor associated with PDAC in this CP cohort, a finding that warrants mechanistic consideration. Although hypercalcemia is classically recognized as a paraneoplastic syndrome in squamous cell carcinoma, breast cancer, and multiple myeloma, often mediated by parathyroid hormone-related protein (PTHrP) secretion or osteolytic metastases[20,21], its association with PDAC has not been well established. Preclinical evidence suggests that certain PDAC cell lines can produce PTHrP, potentially driving humoral hypercalcemia of malignancy[22]. Alternatively, localized bone resorption from occult metastatic disease may also contribute to elevated calcium levels. In contrast, patients with CP typically exhibit hypocalcemia due to fat malabsorption and calcium soap formation[23]. Therefore, the observation of relatively higher ionized calcium levels in the CP-PDAC group, albeit within the normal range, may reflect early paraneoplastic dysregulation. This finding, if validated in future prospective cohorts with measurement of PTHrP and bone turnover markers, could provide a novel biochemical indicator of underlying malignancy. While our findings suggest that elevated serum ionized calcium levels may indicate potential underlying malignancy in patients with CP, the optimal cutoff value could not be determined owing to the limited sample size of the current study and requires further investigation in larger prospective studies.

Consistent with a large body of literature, CA19-9 was confirmed as an independent predictor of PDAC in patients with CP. A prior meta-analysis reported pooled sensitivity and specificity values of approximately 81% for distinguishing PDAC from CP[24]. However, the specificity of CA19-9 is compromised by cholestasis and pancreatitis-related inflammation, limiting its utility as a standalone biomarker[24]. In our subgroup analysis of patients with elevated CA19-9 levels, CEA provided complementary discriminatory information. Although CEA is more commonly applied in colorectal cancer and pancreatic cyst fluid analysis[25], several studies have suggested that combining CA19-9 with CEA may improve the diagnostic specificity for PDAC[26]. Our findings support the use of this dual-biomarker strategy in patients with CP who are being considered for invasive evaluation.

Although pancreatic masses were more frequently observed in patients with PDAC, this radiological finding was not an independent predictor after multivariable adjustment. This observation likely reflects the well-recognized diagnostic challenge posed by mass-forming CP, which may produce desmoplastic reactions and imaging features that are indistinguishable from PDAC[27,28]. In this research, among the 135 patients with mass-forming lesions, 101 (87.07%) of the non-PDAC lesions were localized to the pancreatic head, 11 (9.48%) to the body/tail, and 4 (3.45%) presented as multifocal lesions. In the PDAC group, 16 (84.21%) of the masses were located in the pancreatic head, 2 (10.53%) in the body/tail, and 1 (5.26%) presented as multifocal lesions. Statistical analysis by Fisher’s exact test revealed no significant intergroup difference in lesion location distribution (P = 0.985). The median maximum mass-diameter perpendicular to the main pancreatic duct was 34.8 (IQR: 30.8-37.5) mm in the non-PDAC group compared to 30.6 (IQR: 30.1-36.3) mm in the PDAC group; the Mann-Whitney U test identified no significant between-group discrepancy (P = 0.423). Additionally, smoking and alcohol consumption are well-established risk factors for both CP and PDAC. However, no significant associations were identified in this study[7,29,30].

Several limitations of this study should be considered. First, the relatively modest sample size precluded the determination of optimal biomarker cutoff values and limited the statistical power for subgroup analyses. Second, the retrospective design may have introduced potential selection bias, and certain clinically relevant variables, such as serum immunoglobulin G subclass 4 levels, which are useful in distinguishing autoimmune pancreatitis[31], were incomplete or unavailable. Third, genetic data, including well-known PDAC-associated KRAS mutations[2], PRSS1 mutations associated with hereditary pancreatitis[32] and FUT3 genotypes affecting CA19-9 secretion[33], were unavailable, precluding analysis of these important biological modifiers. The absence of new-onset diabetes status represents a limitation of this study, as this variable has been recognized as a potential indicator of PDAC, especially in individuals older than 50 years[2]. Finally, we recognize the absence of external validation as a notable limitation, which may constrain the generalizability of our conclusions. Further investigations incorporating multi-institutional cohorts or cross-validation designs are needed to confirm our findings.

CONCLUSION

The finding that nearly 1 in 10 patients (9.2%) undergoing invasive treatment for CP harbored occult PDAC supports a lowered threshold for histopathological sampling in this population. Clinicians should maintain a high index of suspicion when patients with CP present with concurrent elevations of CA19-9 and CEA or unexplained elevation of serum ionized calcium levels. Given the aggressive nature of PDAC and the narrow therapeutic window for curative resection, timely identification of malignancy in patients with CP represents a critical unmet clinical need. Future studies should evaluate the utility of integrated biomarker panels, including CA19-9, CEA, and serum ionized calcium, combined with advanced imaging modalities or invasive diagnostic procedures in large, prospective multicenter cohorts of patients with CP.

ACKNOWLEDGEMENTS

We are grateful to Dr. Gui-Ping Xu and Dr. Rui Zhang (Department of Radiology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China) for their expert evaluation of all imaging data and insightful suggestions for this work. We thank the Biobank and Network and Information Center of the First Affiliated Hospital of Xi’an Jiaotong University for providing clinical data.

References
1.  Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10-45.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1828]  [Cited by in RCA: 2948]  [Article Influence: 2948.0]  [Reference Citation Analysis (16)]
2.  Mannucci A, Goel A. Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future. CA Cancer J Clin. 2026;76:e70035.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 3]  [Cited by in RCA: 36]  [Article Influence: 36.0]  [Reference Citation Analysis (5)]
3.  Michl P, Löhr M, Neoptolemos JP, Capurso G, Rebours V, Malats N, Ollivier M, Ricciardiello L. UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better. United European Gastroenterol J. 2021;9:860-871.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 52]  [Cited by in RCA: 51]  [Article Influence: 10.2]  [Reference Citation Analysis (0)]
4.  Thierens N, Verdonk RC, Löhr JM, van Santvoort HC, Bouwense SA, van Hooft JE. Chronic pancreatitis. Lancet. 2025;404:2605-2618.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 6]  [Cited by in RCA: 69]  [Article Influence: 69.0]  [Reference Citation Analysis (2)]
5.  Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol. 2010;24:349-358.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 491]  [Cited by in RCA: 447]  [Article Influence: 27.9]  [Reference Citation Analysis (10)]
6.  Peduzzi G, Archibugi L, Farinella R, Ponz de Leon Pisani R, Vodickova L, Vodicka P, Kraja B, Sainz J, Bars-Cortina D, Daniel N, Silvestri R, Uysal-Onganer P, Landi S, Dulińska-Litewka J, Comandatore A, Campa D, Hughes DJ, Rizzato C. The exposome and pancreatic cancer, lifestyle and environmental risk factors for PDAC. Semin Cancer Biol. 2025;113:100-129.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 2]  [Cited by in RCA: 30]  [Article Influence: 30.0]  [Reference Citation Analysis (0)]
7.  Schneider A, Löhr JM, Singer MV. The M-ANNHEIM classification of chronic pancreatitis: introduction of a unifying classification system based on a review of previous classifications of the disease. J Gastroenterol. 2007;42:101-119.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 390]  [Cited by in RCA: 343]  [Article Influence: 18.1]  [Reference Citation Analysis (0)]
8.  Wolske KM, Ponnatapura J, Kolokythas O, Burke LMB, Tappouni R, Lalwani N. Chronic Pancreatitis or Pancreatic Tumor? A Problem-solving Approach. Radiographics. 2019;39:1965-1982.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 82]  [Cited by in RCA: 63]  [Article Influence: 9.0]  [Reference Citation Analysis (1)]
9.  Munigala S, Subramaniam DS, Subramaniam DP, Burroughs TE, Conwell DL, Sheth SG. Incidence and Risk of Pancreatic Cancer in Patients with a New Diagnosis of Chronic Pancreatitis. Dig Dis Sci. 2022;67:708-715.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 25]  [Cited by in RCA: 20]  [Article Influence: 5.0]  [Reference Citation Analysis (0)]
10.  Kirkegård J, Mortensen FV, Cronin-Fenton D. Chronic Pancreatitis and Pancreatic Cancer Risk: A Systematic Review and Meta-analysis. Am J Gastroenterol. 2017;112:1366-1372.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 435]  [Cited by in RCA: 392]  [Article Influence: 43.6]  [Reference Citation Analysis (5)]
11.  Munigala S, Kanwal F, Xian H, Agarwal B. New diagnosis of chronic pancreatitis: risk of missing an underlying pancreatic cancer. Am J Gastroenterol. 2014;109:1824-1830.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 50]  [Cited by in RCA: 44]  [Article Influence: 3.7]  [Reference Citation Analysis (0)]
12.  Conwell DL, Lee LS, Yadav D, Longnecker DS, Miller FH, Mortele KJ, Levy MJ, Kwon R, Lieb JG, Stevens T, Toskes PP, Gardner TB, Gelrud A, Wu BU, Forsmark CE, Vege SS. American Pancreatic Association Practice Guidelines in Chronic Pancreatitis: evidence-based report on diagnostic guidelines. Pancreas. 2014;43:1143-1162.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 372]  [Cited by in RCA: 306]  [Article Influence: 25.5]  [Reference Citation Analysis (1)]
13.  Vege SS, Chari ST. Chronic Pancreatitis. N Engl J Med. 2022;386:869-878.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 135]  [Cited by in RCA: 122]  [Article Influence: 30.5]  [Reference Citation Analysis (4)]
14.  Kempeneers MA, Issa Y, Ali UA, Baron RD, Besselink MG, Büchler M, Erkan M, Fernandez-Del Castillo C, Isaji S, Izbicki J, Kleeff J, Laukkarinen J, Sheel ARG, Shimosegawa T, Whitcomb DC, Windsor J, Miao Y, Neoptolemos J, Boermeester MA; Working group for the International (IAP – APA – JPS – EPC) Consensus Guidelines for Chronic Pancreatitis. International consensus guidelines for surgery and the timing of intervention in chronic pancreatitis. Pancreatology. 2020;20:149-157.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 87]  [Cited by in RCA: 80]  [Article Influence: 13.3]  [Reference Citation Analysis (0)]
15.  Yamao K, Takenaka M, Ishikawa R, Okamoto A, Yamazaki T, Nakai A, Omoto S, Kamata K, Minaga K, Matsumoto I, Takeyama Y, Numoto I, Tsurusaki M, Chikugo T, Chiba Y, Watanabe T, Kudo M. Partial Pancreatic Parenchymal Atrophy Is a New Specific Finding to Diagnose Small Pancreatic Cancer (≤10 mm) Including Carcinoma in Situ: Comparison with Localized Benign Main Pancreatic Duct Stenosis Patients. Diagnostics (Basel). 2020;10:445.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 14]  [Cited by in RCA: 44]  [Article Influence: 7.3]  [Reference Citation Analysis (0)]
16.  Mukherjee S, Antony A, Patnam NG, Trivedi KH, Karbhari A, Bhinder KK, Zarrintan A, Fletcher JG, Truty M, Johnson MP, Chari ST, Goenka AH. Next-generation AI for visually occult pancreatic cancer detection in a low-prevalence setting with longitudinal stability and multi-institutional generalisability. Gut. 2026;gutjnl-2025.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 4]  [Cited by in RCA: 8]  [Article Influence: 8.0]  [Reference Citation Analysis (5)]
17.  Alves N, Schuurmans M, Rutkowski D, Saha A, Vendittelli P, Obuchowski N, Liedenbaum MH, Haldorsen IS, Molven A, Yakar D, Geerdink J, van Koeverden S, Riviere DM, Venderink W, de Haas R, Kim N, Löhr JM, Suman G, Maier-Hein KH, Hahn HK, Wang W, Yuille AL, Kambadakone A, Fishman EK, Verbeke C, Litjens G, Hermans JJ, Huisman H; PANORAMA consortium. Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study. Lancet Oncol. 2026;27:116-124.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 23]  [Cited by in RCA: 19]  [Article Influence: 19.0]  [Reference Citation Analysis (2)]
18.  Moore TW, Spiliotopoulos E, Callahan RL, Kirschbaum CW, Bailey CF, Kim HJ, Roskams-Hieter B, Goncalves F, Keith D, Grossberg AJ, Spellman PT, Mills GB, Sears RC, Morgan TK, Ngo TTM. Cell free RNA detection of pancreatic cancer in pre diagnostic high risk and symptomatic patients. Nat Commun. 2025;16:7345.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 5]  [Reference Citation Analysis (0)]
19.  Greenhalf W, Lévy P, Gress T, Rebours V, Brand RE, Pandol S, Chari S, Jørgensen MT, Mayerle J, Lerch MM, Hegyi P, Kleeff J, Castillo CF, Isaji S, Shimosegawa T, Sheel A, Halloran CM, Garg P, Takaori K, Besselink MG, Forsmark CE, Wilcox CM, Maisonneuve P, Yadav D, Whitcomb D, Neoptolemos J; Working group for the International (IAP – APA – JPS – EPC) Consensus Guidelines for Chronic Pancreatitis. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club. Pancreatology. 2020;20:910-918.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 64]  [Cited by in RCA: 61]  [Article Influence: 10.2]  [Reference Citation Analysis (3)]
20.  Jick S, Li L, Gastanaga VM, Liede A. Prevalence of hypercalcemia of malignancy among cancer patients in the UK: analysis of the Clinical Practice Research Datalink database. Cancer Epidemiol. 2015;39:901-907.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 42]  [Cited by in RCA: 34]  [Article Influence: 3.1]  [Reference Citation Analysis (2)]
21.  Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr. 2000;10:159-178.  [PubMed]  [DOI]
22.  Pitarresi JR, Norgard RJ, Chiarella AM, Suzuki K, Bakir B, Sahu V, Li J, Zhao J, Marchand B, Wengyn MD, Hsieh A, Kim IK, Zhang A, Sellin K, Lee V, Takano S, Miyahara Y, Ohtsuka M, Maitra A, Notta F, Kremer R, Stanger BZ, Rustgi AK. PTHrP Drives Pancreatic Cancer Growth and Metastasis and Reveals a New Therapeutic Vulnerability. Cancer Discov. 2021;11:1774-1791.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 54]  [Cited by in RCA: 53]  [Article Influence: 10.6]  [Reference Citation Analysis (2)]
23.  D'Souza A, Floch MH. Calcium metabolism in pancreatic disease. Am J Clin Nutr. 1973;26:352-361.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 16]  [Cited by in RCA: 12]  [Article Influence: 0.2]  [Reference Citation Analysis (0)]
24.  Su SB, Qin SY, Chen W, Luo W, Jiang HX. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol. 2015;21:4323-4333.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in CrossRef: 37]  [Cited by in RCA: 52]  [Article Influence: 4.7]  [Reference Citation Analysis (1)]
25.  Kwan MC, Pitman MB, Fernandez-Del Castillo C, Zhang ML. Revisiting the performance of cyst fluid carcinoembryonic antigen as a diagnostic marker for pancreatic mucinous cysts: a comprehensive 20-year institutional review. Gut. 2024;73:629-638.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1]  [Cited by in RCA: 10]  [Article Influence: 5.0]  [Reference Citation Analysis (1)]
26.  Steinberg WM, Gelfand R, Anderson KK, Glenn J, Kurtzman SH, Sindelar WF, Toskes PP. Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology. 1986;90:343-349.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 141]  [Cited by in RCA: 150]  [Article Influence: 3.8]  [Reference Citation Analysis (2)]
27.  Zhang H, Meng Y, Li Q, Yu J, Liu F, Fang X, Li J, Feng X, Zhou J, Zhu M, Li N, Lu J, Shao C, Bian Y. Two nomograms for differentiating mass-forming chronic pancreatitis from pancreatic ductal adenocarcinoma in patients with chronic pancreatitis. Eur Radiol. 2022;32:6336-6347.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 7]  [Cited by in RCA: 13]  [Article Influence: 3.3]  [Reference Citation Analysis (0)]
28.  Ma J, Zhang N, Jiang W, Jin Z, Wang K. Endoscopic ultrasound diagnosis and management of mass-forming chronic pancreatitis with situs inversus. Endoscopy. 2026;58:E582-E583.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 1]  [Reference Citation Analysis (0)]
29.  Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT, Negri E, Li D, Risch HA, Olson SH, Gallinger S, Miller AB, Bueno-de-Mesquita HB, Talamini R, Polesel J, Ghadirian P, Baghurst PA, Zatonski W, Fontham E, Bamlet WR, Holly EA, Bertuccio P, Gao YT, Hassan M, Yu H, Kurtz RC, Cotterchio M, Su J, Maisonneuve P, Duell EJ, Boffetta P, La Vecchia C. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol. 2012;23:1880-1888.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 322]  [Cited by in RCA: 304]  [Article Influence: 21.7]  [Reference Citation Analysis (3)]
30.  Pang Y, Holmes MV, Guo Y, Yang L, Bian Z, Chen Y, Iona A, Millwood IY, Bragg F, Chen J, Li L, Kartsonaki C, Chen Z. Smoking, alcohol, and diet in relation to risk of pancreatic cancer in China: a prospective study of 0.5 million people. Cancer Med. 2018;7:229-239.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 14]  [Cited by in RCA: 33]  [Article Influence: 3.7]  [Reference Citation Analysis (1)]
31.  Sugumar A, Chari ST. Distinguishing pancreatic cancer from autoimmune pancreatitis: a comparison of two strategies. Clin Gastroenterol Hepatol. 2009;7:S59-S62.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 39]  [Cited by in RCA: 34]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
32.  Mahapatra SJ, Chowdhury SD, Akshintala VS, Garg PK. Chronic Pancreatitis: Mechanisms of Inflammation, Pathways of Progression and Emerging Therapeutic Strategies. Gastroenterology. 2026;S0016-5085(26)00355.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1]  [Cited by in RCA: 3]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
33.  Ando Y, Dbouk M, Yoshida T, Saba H, Abou Diwan E, Yoshida K, Dbouk A, Blackford AL, Lin MT, Lennon AM, Burkhart RA, He J, Sokoll L, Eshleman JR, Canto MI, Goggins M. Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer. J Clin Oncol. 2024;42:2196-2206.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 33]  [Cited by in RCA: 27]  [Article Influence: 13.5]  [Reference Citation Analysis (0)]
Footnotes

Peer review: Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Oncology

Country of origin: China

Peer-review report’s classification

Scientific quality: Grade C, Grade D

Novelty: Grade D, Grade D

Creativity or innovation: Grade D, Grade D

Scientific significance: Grade C, Grade D

P-Reviewer: Bhinder KK, Research Fellow, United States S-Editor: Lin C L-Editor: A P-Editor: Zhao S

Write to the Help Desk